Small mobile services company Idogen will have to liquidate the company if some other solution, such as an opposing merger or the sale of its platform, is not quickly found as its money dwindles.
On Tuesday, Sweden’s Idogen (STO: $IDOGEN) said it had begun talks on an opposite merger; However, there is still plenty of time to discuss a liquidation proposal at its annual general meeting on June 8. Idogen added that unless its generation platform is sold and “produces the desired result,” shareholders cannot count on any monetary gain in the event of liquidation.
Unlock this item and others by subscribing to one of our paid plans.
We live in a new era of healthcare that advances and impacts patient outcomes and experiences. We have noticed a remarkable speed of transformative innovation, implemented studies, and complex clinical progression over the past decade.
Despite this great progress, there is still much work to be done and patients are counting on us, now more than ever, to continue this momentum. challenging diseases, adding those that today have few or no effective remedies.
Amylyx Pharmaceuticals’ ALS drug appears to be following a more complicated path in the EU than in the US. USA and Canada.
Biotech announced Tuesday morning that the bloc’s drug review committee, known as CHMP, is expected to have a “negative opinion” and oppose approving the drug next month. If this negative opinion materializes, Amylyx hopes to appeal as part of a “formal review. “”, according to a corporate press release.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
As a number of gene treatment startups aim to create remedies without the inevitable back and forth of an AAV virus, and several gene-editing biotechnologies seek to do the same, the said venture is coming to an end.
Summation Bio, subsidized through at least $24 million in Series A funding, is “shutting down operations” next month, according to an update to a worker’s LinkedIn profile. (According to his LinkedIn profile, one worker said the company raised $60 million in the round. )Another worker visited the networking site last week to say the cases were “second to none” and noted that “despite all efforts and error-free execution, the science, this time, was elusive. “
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Pfizer’s once-weekly antibody treatment for hemophilia A and B helped reduce bleeding cases in patients compared to its previous treatment of infusions of blood-clotting things, the pharmaceutical company announced Tuesday morning.
The open-label phase III study enrolled another 116 people with hemophilia who were first treated for six months with normal or on-demand infusions of thing VIII or IX, the clotting things that hemophilia A and B patients lack. Then, either team switched to the remedy once a week with Pfizer’s marstacimab antibody for a year.
Unlock this item and others by subscribing to one of our paid plans.
While one of its main bets on multiple sclerosis is stuck at a one-year partial clinical suspension, Sanofi has new medium-term insights into another investigational MS remedy that the company says will lay the groundwork for pivotal trials next year.
On Wednesday, the French pharmaceutical company said its experimental drug, frexalimab, was better than placebo at reducing certain types of brain damage, as seen in an MRI at week 12. The study included another 129 people with relapsing sclerosis.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
The FDA imposed a clinical suspension on PepGen’s IND for a drug for myotonic dystrophy 1 (T1DM), halting the company’s plans to introduce a momentary neuromuscular program into the clinic.
PepGen elaborated on what concerns it, saying only that the FDA will provide an official letter within 30 days stating the reasons for the suspension.
Originating from the University of Oxford and supported through RA Capital, PepGen specialises in oligonucleotides (short strands of artificial DNA or RNA molecules) that are delivered with special peptides that enter cells. By conjugating peptides with oligonucleotides, biotechnology promises the absorption and activity of the resulting therapy. .
Unlock this item and others by subscribing to one of our paid plans.
Rain Oncology will lay off 65% of its workers, prevent patient enrollment in a group trial and forgo examining its only asset after a phase III failure last week.
The Newark, California-based biotech had about 70 workers at the time of the announcement last week, meaning 40 to 50 workers will be affected by the layoffs, CEO and co-founder Avanish Vellanki said in an email to Endpoints News. That includes Chief Medical Officer Richard Bryce, who will hand over his duties to Robert Doebele, Rain’s co-founder, president and chief clinical officer, the biotech said in a news release Tuesday.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Glyscend Therapeutics published leading knowledge for its polymer targeting type 2 diabetes and obesity, with the expectation that the candidate will have the same effects as bariatric surgery without the headaches of baseline invasive procedures.
The gut-directed oral polymer, dubbed GLY-200, showed significant and clinically applicable discounts in glucose after eating and decreased body weight and food intake in the company’s 51 participants in the company’s Phase IIa trial. Patients took either the polymer or a placebo twice for 14 days.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
China’s market regulator, the State Administration for Market Regulation, said on Sunday it had fined and confiscated the revenues of two drugmakers for what it called a monopoly deal.
Grand Pharmaceutical fined $19. 68 million (139. 3 million yuan) and the regulator seized $21 million (149 million yuan) of what it called “illegal income” for entering into a monopoly with Wuhan Healcare Pharmaceuticals on two drugs and their active pharmaceutical ingredients (APIs): Norepinephrine Bitartrate and Epinephrine.
Unlock this item and others by subscribing to one of our paid plans.
© Endpoints 2023 News
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.